Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/13 cls

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)

Baird

Thomas Russo

Price target

Market outperform

56%

$12.37

Leerink

Howard Liang

Price target

Market outperform

Piper Jaffray

Edward Tenthoff

Price target

Overweight

William Blair

Y. Katherine Xu

Price target

Market outperform

Russo raised his target to $15 from $9 based on "positive, de-risking" data from a Phase IIa trial of ACH-1625 to treat chronic HCV genotype 1 (see B18). The 12-week, interim data showed once-daily 200, 400 and 800 mg ACH-1625 plus standard of care led to a rapid viral response (RVR) in 67%, 80% and 100% of treatment-naïve patients, respectively, and 100% of patients treated at the doses through 12 weeks achieved complete early virologic response (cEVR). "Most importantly," Russon noted, the data showed safety was "uneventful" at the end of the 12-week treatment. ACH-1625 is a selective inhibitor of HCV NS3 protease.